EVOLUS INC
EOLSNASDAQTrading Snapshot
- Day Range
- $7.91 – $8.12
- 52-Week Range
- $3.86 – $9.31
- Volume
- $2.57B
- Avg Volume
- $3.36B
- Shares Outstanding
- 65.9M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $297M
- Last Q Revenue
- $84M
- P/E Ratio
- -15.4
- P/S Ratio
- 1.7x
- EPS (TTM)
- $-0.52
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.7%
Why Investors Own EOLS
- ✓High-growth profile — revenue up +33.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EVOLUS INC
EOLS
StockOtter · stockotter.spaceAbout EVOLUS INC
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
BlackRock Inc. acquired a new stake in shares of Evolus, Inc. (NASDAQ: EOLS) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 4,840,828 shares of the company's stock, val
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings
Evolus (NASDAQ:EOLS) Reaches New 52-Week High – Time to Buy?
Evolus, Inc. (NASDAQ: EOLS - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $8.82 and last traded at $8.78, with a volume of 1320192 shares. The s
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Assenagon Asset Management S.A. lifted its holdings in Evolus, Inc. (NASDAQ: EOLS) by 51.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institut
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings